相关实验视频

Updated: May 3, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

最近关于脂卡林类蛋白质小分子抑制剂的进展

Siliang Chen^1,2, Zhaoping Pan^1,2, Mingxia Liu²

¹Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu 610041, China.

Journal of medicinal chemistry

|March 25, 2024

概括

脂质转移蛋白 (LTP) 具有卡林域,对于细胞功能和疾病至关重要. 开发这些蛋白质的小分子抑制剂为治疗各种疾病提供了潜在的临床应用.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

脂质转移蛋白 (LTPs) 促进非膀性脂质的运输.
卡林类蛋白质是LTP的一个子集,调节关键的细胞过程,包括免疫反应,增殖,分化和细胞死亡.
这些蛋白质的失调与炎症,代谢,神经系统疾病和癌症有关.

研究的目的:

审查关键的卡林类蛋白质的结构和功能:视网醇结合蛋白,卡林和脂肪酸结合蛋白.
总结一下最近在开发针对这些蛋白质家族的小分子抑制剂方面取得的进展.
讨论这些抑制剂在疾病治疗中的治疗潜力和挑战.

主要方法:

文献综述和综合现有关于卡林类蛋白质的研究.
对视网醇结合蛋白,脂卡林和脂肪酸结合蛋白的结构功能关系的分析.
审查关于小分子抑制剂开发及其临床前/临床应用的最新研究.

主要成果:

类似利波卡林的蛋白质表现出多样化的生物作用,使它们成为有吸引力的治疗点.
针对这些蛋白质的几种小分子抑制剂在各种疾病的临床前研究中显示出有前途.
了解结构-功能动态是设计有效和特定抑制剂的关键.

结论:

用小分子抑制剂向卡林类LTPs为一系列疾病提供了一个有前途的治疗策略.
需要进一步的研究来克服抑制剂开发的挑战,包括特异性和临床疗效.
这一观点为未来该领域的药物开发工作提供了指导.

更多相关视频

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...